reports
- Damien Conover
Astra Posts Solid 2Q, Driven by Strong Cancer Drug Sales and Moving Aw...
We don't expect any major changes to our AstraZeneca fair value estimate following second-quarter results that largely fell in line with our expectations and slightly ahead of consensus expectations. Overall, the company is posting leading Big Pharma sales growth with total sales up 18% operationally year over year, led by impressive cancer drug sales growth of 57%. Astra's ability to continue to bring next generation drugs to the market that address unmet medical need (especially in oncology) s...
- Damien Conover
Astra Posts Solid 2Q, Driven by Strong Cancer Drug Sales and Moving Aw...
We don't expect any major changes to our AstraZeneca fair value estimate following second-quarter results that largely fell in line with our expectations and slightly ahead of consensus expectations. Overall, the company is posting leading Big Pharma sales growth with total sales up 18% operationally year over year, led by impressive cancer drug sales growth of 57%. Astra's ability to continue to bring next generation drugs to the market that address unmet medical need (especially in oncology) s...
- Damien Conover
Progress With Senate Drug Pricing Reform Fits Our Prior Analysis; No F...
Senate Finance Committee Chairman Chuck Grassley and Democratic ranking member Ron Wyden posted the Prescription Drug Pricing Reduction Act on Tuesday, and although this is not a final bill (it needs to proceed through markup on Thursday and get a majority vote of the full committee, so it could see changes before it proceeds to a Senate floor vote), it likely means that a bipartisan agreement was reached prior to posting. Share prices of drug firms were largely unmoved by this news; while we th...
- Damien Conover
Progress With Senate Drug Pricing Reform Fits Our Prior Analysis; No F...
Senate Finance Committee Chairman Chuck Grassley and Democratic ranking member Ron Wyden posted the Prescription Drug Pricing Reduction Act on Tuesday, and although this is not a final bill (it needs to proceed through markup on Thursday and get a majority vote of the full committee, so it could see changes before it proceeds to a Senate floor vote), it likely means that a bipartisan agreement was reached prior to posting. Share prices of drug firms were largely unmoved by this news; while we th...
- Damien Conover
Morningstar | Glaxo Posts Solid 2Q, Buoyed by Strong Vaccine Sales tha...
Glaxo reported second-quarter results that were slightly ahead of both our and consensus expectations, driven by robust vaccine sales, but we don't plan to change our fair value estimate based on the minor outperformance. We continue to view the stock as modestly undervalued, with potential long-term growth not fully factored into the share price. Strong growth in the vaccine unit, steady gains in consumer products, and the ability to mitigate generic Advair competition in the quarter helps rein...
- Damien Conover
Morningstar | Glaxo Posts Solid 2Q, Buoyed by Strong Vaccine Sales tha...
Glaxo reported second-quarter results that were slightly ahead of both our and consensus expectations, driven by robust vaccine sales, but we don't plan to change our fair value estimate based on the minor outperformance. We continue to view the stock as modestly undervalued, with potential long-term growth not fully factored into the share price. Strong growth in the vaccine unit, steady gains in consumer products, and the ability to mitigate generic Advair competition in the quarter helps rein...
- Damien Conover
Glaxo Posts Solid 2Q, Buoyed by Strong Vaccine Sales that Look Poised ...
Glaxo reported second-quarter results that were slightly ahead of both our and consensus expectations, driven by robust vaccine sales, but we don't plan to change our fair value estimate based on the minor outperformance. We continue to view the stock as modestly undervalued, with potential long-term growth not fully factored into the share price. Strong growth in the vaccine unit, steady gains in consumer products, and the ability to mitigate generic Advair competition in the quarter helps rein...
- Damien Conover
Glaxo Posts Solid 2Q, Buoyed by Strong Vaccine Sales that Look Poised ...
Glaxo reported second-quarter results that were slightly ahead of both our and consensus expectations, driven by robust vaccine sales, but we don't plan to change our fair value estimate based on the minor outperformance. We continue to view the stock as modestly undervalued, with potential long-term growth not fully factored into the share price. Strong growth in the vaccine unit, steady gains in consumer products, and the ability to mitigate generic Advair competition in the quarter helps rein...
- Damien Conover
Morningstar | Henry Schein's 1Q Results Show Restructuring Progress
Henry Schein's fiscal first-quarter results broadly met our expectations, and we are reiterating our no-moat rating. We anticipate a potential slight increase to our fair value estimate after we incorporate management's minor lift in 2019 outlook. The company raised the top end of its non-GAAP 2019 EPS guidance range by four cents, which now spans $3.38-$3.50 (versus our previous estimate of $3.40). We continue to view 2019 as a transitional year for Henry Schein, as the company works through it...
- Damien Conover
Morningstar | Dentsply Sirona's 1Q Results Show Restructuring Efforts ...
Dentsply Sirona's first-quarter results mostly met our expectations. We anticipate a minor increase in our fair value estimate, as we think Dentsply's restructuring efforts are starting to materially bear fruit, and we are reiterating our no-moat rating. Dentsply reiterated its full-year outlook while narrowing its adjusted 2019 EPS guidance range to $2.30-$2.40 (from $2.25-$2.40), which still encompasses our previous $2.32 estimate. Although the overall gross profit margin dropped 20 basis poin...
- Damien Conover
Morningstar | Henry Schein's 1Q Results Show Restructuring Progress. S...
Henry Schein's fiscal first-quarter results broadly met our expectations, and we are reiterating our no-moat rating. We anticipate a potential slight increase to our fair value estimate after we incorporate management's minor lift in 2019 outlook. The company raised the top end of its non-GAAP 2019 EPS guidance range by four cents, which now spans $3.38-$3.50 (versus our previous estimate of $3.40). We continue to view 2019 as a transitional year for Henry Schein, as the company works through it...
- Damien Conover
Morningstar | Patterson Posts Mixed 4Q Results Alongside Tepid Fiscal ...
Patterson reported mixed fiscal 2019 fourth-quarter results. We may slightly reduce our fair value estimate as we incorporate management's lower-than-expected 2020 guidance, and we are leaving our no-moat rating intact. Management issued fiscal 2020 adjusted EPS guidance of $1.33-$1.43 which is slightly below our prior estimate of $1.47. While we are encouraged by Patterson's continued efforts to manage costs, we remain concerned about long-term dental headwinds. Patterson's dental business hel...
- Damien Conover
Morningstar | Straumann's 1Q Performance Broadly Met Our Expectations ...
Straumann's fiscal first-quarter earnings results showed strength across its core businesses and broadly met our expectations. The company reiterated its 2019 outlook, and we do not anticipate major changes to our fair value estimate or our narrow moat rating. Despite a degree of seasonal digital hardware softness, the company still posted double-digit organic revenue growth across all regions. Straumann posted healthy growth across all regions during the period, mainly thanks to its implant bu...
- Damien Conover
Morningstar | Align's 1Q Results Show Robust Clear Aligner Growth Desp...
Align reported first-quarter results that mostly met our expectations. We do not anticipate any changes to our $276 fair value estimate, and our narrow moat rating is intact. Despite the company's abrupt Invisalign retail store closures, volume growth of clear aligners continued thanks to broad strength across all geographies and customer channels. Meanwhile, worldwide average selling prices for clear aligners continued to improve sequentially, but fell roughly 5% from the year-ago period. Inv...
- Damien Conover
Morningstar | Align's 1Q Results Show Robust Clear Aligner Growth Desp...
Align reported first-quarter results that mostly met our expectations. We do not anticipate any changes to our $276 fair value estimate, and our narrow moat rating is intact. Despite the company's abrupt Invisalign retail store closures, volume growth of clear aligners continued thanks to broad strength across all geographies and customer channels. Meanwhile, worldwide average selling prices for clear aligners continued to improve sequentially, but fell roughly 5% from the year-ago period. Inv...
- Damien Conover
Morningstar | PerkinElmer's First-Quarter Results Broadly Met Our Expe...
PerkinElmer's fourth-quarter performance mostly tracked our expectations. We do not anticipate any major changes to our fair value estimate after we update our assumptions, and we are leaving our no-moat rating intact. Management slightly lifted its adjusted 2019 EPS guidance range to $4.02-$4.07 (up from $4.00-$4.05) and encompasses our previously forecast $4.02. We view the outlook as realistic as we continue to think the company will benefit from new Cisbio opportunities and broad endmarket s...
- Damien Conover
Morningstar | Dr. Reddy's Fiscal Fourth-Quarter Results Broadly Met Ou...
Dr. Reddy's fiscal fourth-quarter results mostly tracked our expectations. While the company's North American generics top line continued to improve, we don't anticipate any major changes to our fair value estimate, and we are reiterating our no-moat rating. The company's global generic revenue performance was healthy across regions during the quarter. The segment's overall revenue grew by roughly 9%, with robust strength across the board. Dr. Reddy's generic drug revenue saw roughly 27% growth...
- Damien Conover
Morningstar | Dr. Reddy's Fiscal Fourth-Quarter Results Broadly Met Ou...
Dr. Reddy's fiscal fourth-quarter results mostly tracked our expectations. While the company's North American generics top line continued to improve, we don't anticipate any major changes to our fair value estimate, and we are reiterating our no-moat rating. The company's global generic revenue performance was healthy across regions during the quarter. The segment's overall revenue grew by roughly 9%, with robust strength across the board. Dr. Reddy's generic drug revenue saw roughly 27% growth...
- Damien Conover
Morningstar | Dr. Reddy's Fiscal Fourth-Quarter Results Broadly Met Ou...
Dr. Reddy's fiscal fourth-quarter results mostly tracked our expectations. While the company's North American generics top line continued to improve, we don't anticipate any major changes to our fair value estimate, and we are reiterating our no-moat rating. The company's global generic revenue performance was healthy across regions during the quarter. The segment's overall revenue grew by roughly 9%, with robust strength across the board. Dr. Reddy's generic drug revenue saw roughly 27% growth...
- Damien Conover
Morningstar | Dr. Reddy's Fiscal Fourth-Quarter Results Broadly Met Ou...
Dr. Reddy's fiscal fourth-quarter results mostly tracked our expectations. While the company's North American generics top line continued to improve, we don't anticipate any major changes to our fair value estimate, and we are reiterating our no-moat rating. The company's global generic revenue performance was healthy across regions during the quarter. The segment's overall revenue grew by roughly 9%, with robust strength across the board. Dr. Reddy's generic drug revenue saw roughly 27% growth...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.